Valuation: CorMedix Inc.

Market Cap 61Cr 53Cr 50Cr 45Cr 85Cr 5.85TCr 85Cr 596.01Cr 230.3Cr 2.97TCr 228.97Cr 223.88Cr 9.45TCr P/E 2026 *
16x
P/E 2027 * 130x
Enterprise Value 61Cr 53Cr 50Cr 45Cr 85Cr 5.85TCr 85Cr 596.01Cr 230.3Cr 2.97TCr 228.97Cr 223.88Cr 9.45TCr EV / Sales 2026 *
1.81x
EV / Sales 2027 * 2.13x
Free-Float
92.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.77%
1 week-3.81%
Current month-5.33%
1 month+3.71%
3 months-9.70%
6 months+19.57%
Current year-32.76%
1 week 7.71
Extreme 7.71
8.06
1 month 7.71
Extreme 7.71
8.74
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
29/08/26 Tax

Chief Operating Officer

-8,076 0.0104%
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%-3.81%-32.53%+100.00% 61Cr
+0.78%-1.78%+78.70%+34.77% 36TCr
+0.34%+0.38%+22.76%-17.82% 6.61TCr
+2.06%+0.98%+42.97%+176.49% 1.23TCr
+1.98%+2.56%-5.10%-16.27% 748.95Cr
+0.13%-6.68%-29.36%-14.35% 447.61Cr
-2.52%-3.38%-35.21%+7.50% 421.53Cr
+2.21%+0.06%-32.05%-13.89% 296.25Cr
+0.24%-1.64%-5.93%+41.57% 240.53Cr
+1.25%-0.71%-26.04%-32.99% 194.71Cr
Average +0.60%-1.27%-2.18%+26.50% 4.6TCr
Weighted average by Cap. -0.22%-1.54%+64.50%+28.98%

Financials

2026 *2027 *
Net sales 34Cr 29Cr 28Cr 25Cr 47Cr 3.23TCr 47Cr 329.62Cr 127.37Cr 1.64TCr 126.63Cr 123.82Cr 5.23TCr 29Cr 25Cr 23Cr 21Cr 40Cr 2.75TCr 40Cr 280.1Cr 108.23Cr 1.39TCr 107.61Cr 105.22Cr 4.44TCr
Net income 4.57Cr 3.96Cr 3.74Cr 3.4Cr 6.36Cr 438.03Cr 6.4Cr 45Cr 17Cr 222.17Cr 17Cr 17Cr 708.17Cr 56.86L 49.27L 46.57L 42.28L 79.24L 55Cr 79.71L 5.56Cr 2.15Cr 28Cr 2.14Cr 2.09Cr 88Cr
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
16/26/16 $7.820 +0.77% 6,64,712
15/26/15 $7.760 -1.65% 7,18,708
14/26/14 $7.890 +0.83% 9,20,272
11/26/11 $7.825 -1.70% 8,20,993
10/26/10 $7.960 -2.09% 8,57,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.820USD
Average target price
15.40USD
Spread / Average Target
+96.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!